Hangzhou Tigermed Consulting Co., Ltd. (HNGZY)
USD 4.0
(0.0%)
USD 4.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 2.02 Billion USD | -4.47% |
| 2022 | 299.4 Million USD | -32.93% |
| 2021 | 446.41 Million USD | 75.94% |
| 2020 | 253.73 Million USD | 108.41% |
| 2019 | 121.74 Million USD | -74.22% |
| 2018 | 472.18 Million CNY | 56.86% |
| 2017 | 301.01 Million CNY | 114.01% |
| 2016 | 140.65 Million CNY | -10.0% |
| 2015 | 156.27 Million CNY | 24.53% |
| 2014 | 125.49 Million CNY | 33.43% |
| 2013 | 94.05 Million CNY | 38.83% |
| 2012 | 67.74 Million CNY | 41.76% |
| 2011 | 47.79 Million CNY | 50.72% |
| 2010 | 31.7 Million CNY | 306.48% |
| 2009 | 7.8 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 320.58 Million CNY | 24.36% |
| 2024 Q1 | 235.07 Million CNY | 61.84% |
| 2024 Q2 | 257.77 Million CNY | 9.66% |
| 2023 Q2 | 819.88 Million CNY | 886.82% |
| 2023 FY | 286.02 Million USD | -4.47% |
| 2023 Q1 | 83.08 Million USD | 47.11% |
| 2023 Q4 | 145.24 Million CNY | -70.43% |
| 2023 Q3 | 491.26 Million CNY | -40.08% |
| 2022 Q3 | 60.21 Million USD | -91.06% |
| 2022 Q4 | 56.47 Million USD | -6.21% |
| 2022 Q2 | 673.58 Million CNY | 29.93% |
| 2022 Q1 | 518.41 Million CNY | -52.57% |
| 2022 FY | 299.4 Million USD | -32.93% |
| 2021 Q2 | 123.81 Million CNY | 76.13% |
| 2021 FY | 446.41 Million USD | 75.94% |
| 2021 Q3 | 526.07 Million CNY | 324.89% |
| 2021 Q4 | 1.09 Billion CNY | 107.79% |
| 2021 Q1 | 70.29 Million CNY | -83.72% |
| 2020 Q2 | 743.84 Million CNY | 191.75% |
| 2020 Q3 | 319.21 Million CNY | -57.09% |
| 2020 Q4 | 431.75 Million CNY | 35.26% |
| 2020 FY | 253.73 Million USD | 108.41% |
| 2020 Q1 | 254.96 Million CNY | -18.68% |
| 2019 Q3 | 176 Million CNY | -14.81% |
| 2019 Q4 | 313.51 Million CNY | 78.12% |
| 2019 FY | 121.74 Million USD | -74.22% |
| 2019 Q1 | 145.5 Million CNY | -5.68% |
| 2019 Q2 | 206.61 Million CNY | 41.99% |
| 2018 Q1 | 95.9 Million CNY | -4.72% |
| 2018 FY | 472.18 Million CNY | 56.86% |
| 2018 Q3 | 99.26 Million CNY | -19.13% |
| 2018 Q4 | 154.26 Million CNY | 55.4% |
| 2018 Q2 | 122.74 Million CNY | 27.99% |
| 2017 Q3 | 80.73 Million CNY | 5.88% |
| 2017 FY | 301.01 Million CNY | 114.01% |
| 2017 Q4 | 100.65 Million CNY | 24.67% |
| 2017 Q2 | 76.24 Million CNY | 75.76% |
| 2017 Q1 | 43.38 Million CNY | 5.85% |
| 2016 Q1 | 40.2 Million CNY | -12.15% |
| 2016 Q2 | 37.94 Million CNY | -5.64% |
| 2016 FY | 140.65 Million CNY | -10.0% |
| 2016 Q4 | 40.98 Million CNY | 90.47% |
| 2016 Q3 | 21.51 Million CNY | -43.29% |
| 2015 Q2 | 40.04 Million CNY | 11.61% |
| 2015 Q3 | 34.58 Million CNY | -13.64% |
| 2015 Q4 | 45.77 Million CNY | 32.35% |
| 2015 Q1 | 35.87 Million CNY | -11.79% |
| 2015 FY | 156.27 Million CNY | 24.53% |
| 2014 Q2 | 27.46 Million CNY | 2.65% |
| 2014 Q1 | 26.75 Million CNY | 0.1% |
| 2014 FY | 125.49 Million CNY | 33.43% |
| 2014 Q4 | 40.67 Million CNY | 32.94% |
| 2014 Q3 | 30.59 Million CNY | 11.41% |
| 2013 FY | 94.05 Million CNY | 38.83% |
| 2013 Q1 | 21.92 Million CNY | 2.59% |
| 2013 Q3 | 21.06 Million CNY | -13.42% |
| 2013 Q4 | 26.73 Million CNY | 26.87% |
| 2013 Q2 | 24.33 Million CNY | 11.0% |
| 2012 Q1 | 14.84 Million CNY | -1.02% |
| 2012 Q3 | 14.17 Million CNY | -18.33% |
| 2012 Q4 | 21.36 Million CNY | 50.76% |
| 2012 FY | 67.74 Million CNY | 41.76% |
| 2012 Q2 | 17.35 Million CNY | 16.87% |
| 2011 Q3 | 9.94 Million CNY | 0.0% |
| 2011 Q4 | 15 Million CNY | 50.86% |
| 2011 FY | 47.79 Million CNY | 50.72% |
| 2010 FY | 31.7 Million CNY | 306.48% |
| 2009 FY | 7.8 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.41 Million USD | 143706.382% |
| Arrayit Corporation | -3.31 Million USD | 61170.505% |
| Atlantic International Corp. | -5.62 Million USD | 36080.76% |
| Biocept, Inc. | -32.08 Million USD | 6410.5% |
| Bioqual, Inc. | 483.48 Thousand USD | -418706.528% |
| CardioGenics Holdings Inc | -1.91 Million USD | 105763.238% |
| DermTech, Inc. | -100.88 Million USD | 2107.028% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| HTG Molecular Diagnostics, Inc. | -21.59 Million USD | 9476.704% |
| iMD Companies, Inc. | -200.63 Thousand USD | 1009315.689% |
| IDenta Corp. | 14.64 Thousand USD | -13827064.634% |
| Interpace Biosciences, Inc. | 802 Thousand USD | -252375.061% |
| Integrative Health Technologies, Inc. | 38.68 Thousand USD | -5233558.117% |
| InVitro International | 1553.00 USD | -130383028.719% |
| Lumos Diagnostics Holdings Limited | -8.59 Million USD | 23666.69% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | 3484492.189% |
| Medical Imaging Corp. | -3.02 Million USD | 67080.943% |
| NovelStem International Corp. | -4.18 Million USD | 48456.936% |
| Optigenex Inc. | -2.89 Million USD | 69976.387% |
| PharmChem, Inc. | 845.1 Thousand USD | -239498.296% |
| Proteome Sciences plc | -2.44 Million USD | 82983.749% |
| Response Genetics, Inc | -20.18 Million USD | 10131.956% |
| Rennova Health, Inc. | -3.29 Million USD | 61588.496% |
| RushNet, Inc. | -607.02 Thousand USD | 333667.807% |
| ScreenPro Security Inc. | -2.24 Million USD | 90142.676% |
| Stella Diagnostics Inc. | -5.7 Million USD | 35577.451% |
| StageZero Life Sciences Ltd. | -11.41 Million USD | 17837.924% |
| Todos Medical Ltd. | -24.99 Million USD | 8201.344% |